 Moderna Inc NASDAQ:MRNA is up 23.6 at 204.04 at last check, after a mid-stage trial showed the combination of its experimental melanoma vaccine and Mercks MRK immunotherapy Keytruda lowered the risk of skin cancers recurrence or death by 44. 